Nitisinone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00348 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | renal tubular acidosis | KG + DL |
| 2 | galactosemia | KG + DL |
| 3 | serpinopathy with toxic serpin polymerization | KG + DL |
| 4 | C1 inhibitor deficiency | KG + DL |
| 5 | glycogen storage disease | KG + DL |
| 6 | adult polyglucosan body disease | KG + DL |
| 7 | glycogen storage disease due to glucose-6-phosphatase deficiency | KG + DL |
| 8 | Griscelli syndrome | KG + DL |
| 9 | granulomatous disease, chronic, X-linked | KG + DL |
| 10 | ermine phenotype | KG + DL |
| 11 | ocular albinism (disease) | KG + DL |
| 12 | piebaldism | KG + DL |
| 13 | ocular albinism with sensorineural deafness | KG + DL |
| 14 | anemia, nonspherocytic hemolytic, due to G6PD deficiency | KG + DL |
| 15 | cold agglutinin disease | KG + DL |
| 16 | primary CD59 deficiency | KG + DL |
| 17 | hemolytic anemia due to diphosphoglycerate mutase deficiency | KG + DL |
| 18 | cholelithiasis | KG + DL |
| 19 | albinism | KG + DL |
| 20 | classic galactosemia | KG + DL |
| 21 | Hermansky-Pudlak syndrome with pulmonary fibrosis | KG + DL |
| 22 | Hermansky-Pudlak syndrome without pulmonary fibrosis | KG + DL |
| 23 | glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form | KG + DL |
| 24 | glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form | KG + DL |
| 25 | oculocerebral hypopigmentation syndrome, Cross type | KG + DL |
| 26 | galactose epimerase deficiency | KG + DL |
| 27 | galactokinase deficiency | KG + DL |
| 28 | tricarboxylic acid cycle disorder | KG + DL |
| 29 | hereditary angioedema with C1Inh deficiency | KG + DL |
| 30 | X-linked recessive ocular albinism | KG + DL |
| 31 | cystinosis | KG + DL |
| 32 | cystinuria | KG + DL |
| 33 | disease of transporter activity | KG + DL |
| 34 | Waardenburg syndrome | KG + DL |
| 35 | temperature-sensitive oculocutaneous albinism type 1 | KG + DL |
| 36 | Pendred syndrome | KG + DL |
| 37 | minimal pigment oculocutaneous albinism type 1 | KG + DL |
| 38 | immune-mediated necrotizing myopathy | KG + DL |
| 39 | focal myositis | KG + DL |
| 40 | mixed-type autoimmune hemolytic anemia | KG + DL |
| 41 | antisynthetase syndrome | KG + DL |
| 42 | drug-induced autoimmune hemolytic anemia | KG + DL |
| 43 | ocular cystinosis | KG + DL |
| 44 | pyruvate metabolism disorder | KG + DL |
| 45 | glycogen storage disease due to glycogen branching enzyme deficiency, non progressive hepatic form | KG + DL |
| 46 | glycogen storage disease due to glycogen branching enzyme deficiency, progressive hepatic form | KG + DL |
| 47 | glycogen storage disease due to glycogen branching enzyme deficiency, adult neuromuscular form | KG + DL |
| 48 | glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form | KG + DL |
| 49 | glycogen storage disease due to glycogen branching enzyme deficiency, childhood combined hepatic and myopathic form | KG + DL |
| 50 | inborn disorder of fatty acid oxidation and ketone body metabolism | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.